Astellas Pharma Inc - Company Profile
Powered by 
All the sales intelligence you need on Astellas Pharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Astellas Pharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Astellas Pharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Astellas Pharma Inc (Astellas) discovers, develops, manufactures and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, cancer, nephrology, infectious diseases, and metabolic diseases, immunodeficiency, and transplantation. The company strives to develop new drugs to address high unmet medical needs with focus on biology and modality. Its pipeline consists of drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Chuo-Ku, Tokyo, Japan.
Headquarters
Japan
Address
2-5-1, Nihombashihon-Cho, Chuo-Ku, Tokyo, 103-8411
Website
www.astellas.com/jp
Telephone
81 3 32443000
No of Employees
13,643
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4503 (TYO)
Revenue (2025)
$13.7B
19.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
197.7%
(2025 vs 2024)
Market Cap*
$23.7B
Net Profit Margin (2024)
XYZ
150.0%
(2025 vs 2024)
* As of and is in US$
Astellas Pharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Xtandi- Treatment of Prostate Cancer | Izervay |
| Xospata- Acute Myeloid Leukemia | Keytruda |
| Padcev- Metastatic Urothelial Cancer | Padcev |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company entered into an agreement to acquire the Fabry Disease Program and Isaralgagene Civaparvovec from Sangamo Therapeutics. |
| 2026 | Contracts/Agreements | In April, the company signed an agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. for Astellas’ Myrbetriq. |
| 2026 | Contracts/Agreements | In February, the company signed a global strategic collaboration agreement with Vir Biotechnology, Inc to develop and commercialize VIR-5500, a PSMA-targeted PRO-XTEN dual -masking CD3 T-cell engager. |
Competitor Comparison
| Key Parameters | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Otsuka Pharmaceutical Co Ltd | Eisai Co Ltd | Kyowa Kirin Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Chiyoda-Ku | Bunkyo-Ku | Chiyoda-Ku |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 13,643 | 19,765 | 6,070 | 10,543 | 5,161 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenji Yasukawa | Chairman | Executive Board | 2023 | - |
| Naoki Okamura | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
| Katsuyoshi Sugita | Chief Ethics Officer; Executive Vice President; Chief People Officer; Chief Compliance Officer; Director | Executive Board | 2023 | - |
| Atsushi Kitamura | Chief Financial Officer | Senior Management | 2023 | - |
| Takahiko Iwaya | Chief Strategy Officer | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer